Clovis Oncology, Inc.
(NASDAQ : CLVS)

( )
CLVS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.81%174.661.2%$575.79m
CELGCelgene Corporation
0.60%89.491.2%$535.84m
GILDGilead Sciences, Inc.
0.42%74.010.9%$421.63m
BIIBBiogen Inc.
-1.41%259.301.2%$416.64m
REGNRegeneron Pharmaceuticals, Inc.
0.56%316.012.7%$245.42m
INCYIncyte Corporation
-0.42%68.142.5%$245.05m
VRTXVertex Pharmaceuticals Incorporated
0.34%158.691.9%$226.49m
ALXNAlexion Pharmaceuticals, Inc.
0.05%107.832.0%$209.17m
NKTRNektar Therapeutics
-0.88%85.456.0%$201.71m
ILMNIllumina, Inc.
0.51%245.853.5%$184.02m
AAgilent Technologies, Inc.
0.74%68.051.5%$157.16m
ALNYAlnylam Pharmaceuticals, Inc
-1.66%95.869.8%$140.19m
BLUEBluebird Bio, Inc.
-1.32%168.2515.8%$127.75m
EXASExact Sciences Corporation
2.48%48.7025.7%$111.34m
BMRNBioMarin Pharmaceutical Inc.
-0.27%82.084.4%$104.77m

Company Profile

Clovis Oncology, Inc. engages in the acquisition, development, and commercialization of anti-cancer agents. Its marketed product, Rubraca, seeks to treat patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies. It also has product candidates, namely Rociletinib and Lucitanib. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.